Sonavane Sunita Nitin, Basu Sandip
Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Parel; Homi Bhabha National Institute, Mumbai, India.
Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Parel; Homi Bhabha National Institute, Mumbai, India.
PET Clin. 2023 Jan;18(1):81-101. doi: 10.1016/j.cpet.2022.09.005. Epub 2022 Oct 28.
PET/computed tomography (CT) studies can be potentially useful in elderly thyroid carcinoma patients for exploring the disease biology, especially in metastatic setting and thereby directing appropriate therapeutic management on case-to-case basis, adopting nuclear theranostics, and disease prognostication. With the availability of multiple PET radiopharmaceuticals, it would be worthwhile to evolve and optimally use FDG and the other non-fluorodeoxyglucose and investigational PET/CT tracers as per the clinical situation and need and thereby define their utilities in a given case scenario. In this regard, (I) differentiated thyroid carcinoma (DTC) including radioiodine refractory disease, poorly differentiated thyroid cancer (PDTC) and TENIS, (II) medullary thyroid carcinoma (MTC), (III) anaplastic carcinoma and (IV) Primary thyroid lymphoma (PTL) should be viewed and dealt separately.
正电子发射断层扫描/计算机断层扫描（PET/CT）研究对于老年甲状腺癌患者探索疾病生物学可能具有潜在的用途，尤其是在转移情况下，从而根据具体情况指导适当的治疗管理，采用核诊疗学方法以及进行疾病预后评估。随着多种PET放射性药物的出现，根据临床情况和需求来研发并优化使用氟脱氧葡萄糖（FDG）以及其他非氟脱氧葡萄糖和研究性PET/CT示踪剂，并由此确定它们在特定病例中的效用，将是很有价值的。在这方面，（I）分化型甲状腺癌（DTC），包括放射性碘难治性疾病、低分化甲状腺癌（PDTC）和TENIS，（II）髓样甲状腺癌（MTC），（III）未分化癌，以及（IV）原发性甲状腺淋巴瘤（PTL）应分别看待和处理。
